ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025

Reuters

09/24

ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025

ESSA Pharma Inc. has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right $(CVR)$ that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2569777136"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569777136\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569777136?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569777136","market":"nz","top_or_hot":-1,"title":"ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-24 18:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma Inc.</a> has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XOMA","symbol_name":"标记临床研究","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL53Zm9:1","article_id":"2569777136","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569777136","pubTimestamp":1758708052,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ESSA Pharma Inc. has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right  that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XOMA":"标记临床研究","BK4139":"生物科技","EPIX":"ESSA Pharma Inc."},"translate_title":"ESSA Pharma更新XenoTherapeutics交易条款，降低股东派息并将特别会议推迟至2025年10月","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XOMA":0.9,"EPIX":0.9},"content_text":"ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025\n    \n\nESSA Pharma Inc. has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right $(CVR)$ that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief on September 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}